-
公开(公告)号：US11912721B2
公开(公告)日：2024-02-27
申请号：US17102790
申请日：2020-11-24
Applicant: UCB Biopharma SRL , Sanofi
Inventor： Teresa De Haro Garcia , Michael Deligny , Jag Paul Heer , Joanna Rachel Quincey , Mengyang Xuan , Zhaoning Zhu , Daniel Christopher Brookings , Mark Daniel Calmiano , Yves Evrard , Martin Clive Hutchings , James Andrew Johnson , Sophie Jadot , Jean Keyaerts , Malcolm MacCoss , Matthew Duncan Selby , Michael Alan Shaw , Dominique Louis Leon Swinnen , Laurent Schio , Yann Foricher , Bruno Filoche-Romme
IPC: C07D519/00 , C07D491/08 , C07D487/08 , C07D491/18 , C07D495/08 , C07D471/18 , C07D487/18 , C07D493/18 , C07D495/18 , C07D513/18 , C07F7/18 , A61K31/4184 , A61K31/506 , A61K31/55
CPC classification number: C07D519/00 , A61K31/4184 , A61K31/506 , A61K31/55 , C07D471/18 , C07D487/08 , C07D487/18 , C07D491/08 , C07D491/18 , C07D493/18 , C07D495/08 , C07D495/18 , C07D513/18 , C07F7/1804
Abstract: A series of fused pentacyclic imidazole derivatives, being potent modulators of human TNFa activity, are accordingly of benefit in the treatment and/or prevention of various human ailments, including autoimmune and inflammatory disorders; neurological and neurodegenerative disorders; pain and nociceptive disorders; cardiovascular disorders; metabolic disorders; ocular disorders; and oncological disorders. In particular, the present invention is concerned with 6, 7-dihydro-7, 14-methanobenzimidazo[1, 2-b][2,5]benzodiazocin-5(14H)-one derivatives and analogs thereof.
-
公开(公告)号：US20210228547A1
公开(公告)日：2021-07-29
申请号：US17058973
申请日：2019-07-08
Applicant: UCB Biopharma SRL
Inventor： Gareth Neil Brace , Daniel Christopher Brookings , Gregory Foulkes , Fabien Claude Lecomte
IPC: A61K31/422 , C07D413/12 , C07D405/12 , C07D491/107 , C07D493/10 , C07D311/96 , C07D491/20 , C07D405/14 , A61K31/4155 , A61K31/427 , A61K31/407 , A61K31/4245 , A61K31/352 , A61K31/437
Abstract: A series of substituted spirocyclic indane derivatives of Formula (I), and analogues thereof, being potent modulators of human IL-17 activity, are accordingly of benefit in the treatment and/or prevention of various human ailments, including inflammatory and autoimmune disorders.
-
公开(公告)号：US20210155637A1
公开(公告)日：2021-05-27
申请号：US17102790
申请日：2020-11-24
Applicant: UCB Biopharma SRL , Sanofi
Inventor： Teresa De Haro Garcia , Michael Deligny , Jag Paul Heer , Joanna Rachel Quincey , Mengyang Xuan , Zhaoning Zhu , Daniel Christopher Brookings , Mark Daniel Calmiano , Yves Evrard , Martin Clive Hutchings , James Andrew Johnson , Sophie Jadot , Jean Keyaerts , Malcolm Mac Coss , Matthew Duncan Selby , Michael Alan Shaw , Dominique Louis Leon Swinnen , Laurent Schio , Yann Foricher , Bruno Filoche-Romme
IPC: C07D519/00 , C07F7/18 , C07D491/08 , A61K31/4184 , A61K31/506 , A61K31/55 , C07D487/08 , C07D491/18 , C07D495/08 , C07D471/18 , C07D487/18 , C07D493/18 , C07D495/18 , C07D513/18
Abstract: A series of fused pentacyclic imidazole derivatives, being potent modulators of human TNFa activity, are accordingly of benefit in the treatment and/or prevention of various human ailments, including autoimmune and inflammatory disorders; neurological and neurodegenerative disorders; pain and nociceptive disorders; cardiovascular disorders; metabolic disorders; ocular disorders; and oncological disorders. In particular, the present invention is concerned with 6,7-dihydro-7,14-methanobenzimidazo[1,2-b][2,5]benzodiazocin-5(14H)-one derivatives and analogs thereof.
-
公开(公告)号：US10953019B2
公开(公告)日：2021-03-23
申请号：US16487988
申请日：2018-03-14
Applicant: UCB Biopharma SRL , Sanofi
Inventor： Julien Alistair Brown , Daniel Christopher Brookings , Jag Paul Heer , James Andrew Johnson , Zhaoning Zhu
IPC: A61K31/55 , C07D471/22
Abstract: A series of substituted fused pentacyclic imidazopyridine and imidazopyridazine derivatives, and analogues thereof, being potent modulators of human TNFα activity, are accordingly of benefit in the treatment and/or prevention of various human ailments, including autoimmune and inflammatory disorders; neurological and neurodegenerative disorders; pain and nociceptive disorders; cardiovascular disorders; metabolic disorders; ocular disorders; and oncological disorders.
-
公开(公告)号：US10883996B2
公开(公告)日：2021-01-05
申请号：US15736336
申请日：2015-10-22
Applicant: UCB BIOPHARMA SRL
Inventor： James Philip O'Connell , John Robert Porter , Alastair Lawson , Boris Kroeplien , Stephen Edward Rapecki , Timothy John Norman , David James McMillan , Graham John Warrellow , Daniel Christopher Brookings , Rikki Peter Alexander
IPC: G01N33/68 , C07K14/525 , C07K14/705 , C07K16/24 , C07D401/14 , C07D471/00 , C07D213/72 , C07D235/04 , C07D239/26 , C07D471/04 , A61K47/64 , A61P37/00 , A61P35/00
Abstract: The invention is in the field of TNF signalling. Compounds have been identified which are capable of modulating signalling of TNF trimers through receptors. Methods of identifying such compounds are therefore provided. The compounds themselves have utility in therapy.
-
Patent Agency Ranking
公开(公告)号：US20230250105A1
公开(公告)日：2023-08-10
申请号：US18175030
申请日：2023-02-27
Applicant: UCB Biopharma SRL , SANOFI
Inventor： Daniel Christopher Brookings , Teresa De Haro Garcia , Yann Foricher , Helen Tracey Horsley , Martin Clive Hutchings , James Andrew Johnson , Malcolm Maccoss , Mengyang Xuan , Zhaoning Zhu
IPC: C07D487/18
CPC classification number: C07D487/18 , C07B2200/05
Abstract: A compound of formula (I) as defined herein, or a pharmaceutically acceptable salt thereof, being potent modulators of human TNFα activity, are accordingly of benefit in the treatment and/or prevention of various human ailments, including autoimmune and inflammatory disorders; neurological and neurodegenerative disorders; pain and nociceptive disorders; cardiovascular disorders; metabolic disorders; ocular disorders; and oncological disorders.
-
公开(公告)号：US11458124B2
公开(公告)日：2022-10-04
申请号：US17058973
申请日：2019-07-08
Applicant: UCB Biopharma SRL
Inventor： Gareth Neil Brace , Daniel Christopher Brookings , Gregory Foulkes , Fabien Claude Lecomte
IPC: C07D405/14 , A61K31/422 , A61K31/352 , A61K31/407 , A61K31/4155 , A61K31/4245 , A61K31/427 , A61K31/437 , C07D311/96 , C07D405/12 , C07D413/12 , C07D491/107 , C07D491/20 , C07D493/10
Abstract: A series of substituted spirocyclic indane derivatives of Formula (I), and analogues thereof, being potent modulators of human IL-17 activity, are accordingly of benefit in the treatment and/or prevention of various human ailments, including inflammatory and autoimmune disorders.
-
公开(公告)号：US20210252012A1
公开(公告)日：2021-08-19
申请号：US17176018
申请日：2021-02-15
Applicant: UCB Biopharma SRL , SANOFI
Inventor： Daniel Christopher Brookings , Teresa De Haro Garcia , Yann Foricher , Helen Tracey Horsley , Martin Clive Hutchings , James Andrew Johnson , Malcolm Maccoss , Mengyang Xuan , Zhaoning Zhu
IPC: A61K31/55 , C07D487/18
Abstract: A compound of formula (I) as defined herein, or a pharmaceutically acceptable salt thereof, being potent modulators of human TNFα activity, are accordingly of benefit in the treatment and/or prevention of various human ailments, including autoimmune and inflammatory disorders; neurological and neurodegenerative disorders; pain and nociceptive disorders; cardiovascular disorders; metabolic disorders; ocular disorders; and oncological disorders.
-
公开(公告)号：US10906919B2
公开(公告)日：2021-02-02
申请号：US16220847
申请日：2018-12-14
Applicant: UCB Biopharma SRL , Sanofi
Inventor： Teresa De Haro Garcia , Michael Deligny , Jag Paul Heer , Joanna Rachel Quincey , Mengyang Xuan , Zhaoning Zhu , Daniel Christopher Brookings , Mark Daniel Calmiano , Yves Evrard , Martin Clive Hutchings , James Andrew Johnson , Sophie Jadot , Jean Keyaerts , Malcolm Mac Coss , Matthew Duncan Selby , Michael Alan Shaw , Dominique Louis Leon Swinnen , Laurent Schio , Yann Foricher , Bruno Filoche-Romme
IPC: C07D519/00 , C07F7/18 , C07D491/08 , A61K31/4184 , A61K31/506 , A61K31/55 , C07D487/08 , C07D491/18 , C07D495/08 , C07D471/18 , C07D487/18 , C07D493/18 , C07D495/18 , C07D513/18
Abstract: A series of fused pentacyclic imidazole derivatives, being potent modulators of human TNFa activity, are accordingly of benefit in the treatment and/or prevention of various human ailments, including autoimmune and inflammatory disorders; neurological and neurodegenerative disorders; pain and nociceptive disorders; cardiovascular disorders; metabolic disorders; ocular disorders; and oncological disorders. In particular, the present invention is concerned with 6,7-dihydro-7,14-methanobenzimidazo[1,2-b][2,5]benzodiazocin-5(14H)-one derivatives and analogs thereof.
-
公开(公告)号：US20250127795A1
公开(公告)日：2025-04-24
申请号：US18819527
申请日：2024-08-29
Applicant: UCB Biopharma SRL , Sanofi
Inventor： Daniel Christopher Brookings , Teresa De Haro Garcia , Yann Foricher , Helen Tracey Horsley , Martin Clive Hutchings , James Andrew Johnson , Malcolm Maccoss , Mengyang Xuan , Zhaoning Zhu
IPC: A61K31/55 , C07D487/18
Abstract: A compound of formula (I) as defined herein, or a pharmaceutically acceptable salt thereof, being potent modulators of human TNFα activity, are accordingly of benefit in the treatment and/or prevention of various human ailments, including autoimmune and inflammatory disorders; neurological and neurodegenerative disorders; pain and nociceptive disorders; cardiovascular disorders; metabolic disorders; ocular disorders; and oncological disorders.
-
-
-
-
-
-
-
-
-
Search Results
11
records
(took 0.016 seconds)
